We present the case of a 69-year-old male patient non sensitized against HLA who underwent a first kidney transplant after diabetic nephropathy. The patient was also diagnosed with idiopathic pulmonar...

Background The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with ...

Medical News: Breakthrough insights into how a key fibrosis drug reshapes immune responses Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease that slowly scars the lungs, making it increasingly difficult for patients to breathe. Scientists have long known that the anti-fibrotic drug nintedanib helps slow disease progression, but exactly how it influences the immune system has remai...

Pediatric Research - Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model

If you’re dealing with idiopathic pulmonary fibrosis (IPF), life already feels heavy. Breathing takes effort. Appointments pile up. Then comes the big question everyone worries about but hates asking: what’s the Nintedanib Price Philippines going to be like long-term? This post is here to keep things simple. No medical lectures. No sales talk. Just a clear look at how people across the Philippines think about treatment costs and what actually matters day to day.

Disease progression was different between IPF and PPF compared with SScILD, but the relative treatment effect was comparable.

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease wit